Oral presentation

Oral presentations can cover: original research findings, case studies, completed projects and theoretical analysis. Presentations should be well structured, rigorous and demonstrate a novel contribution to knowledge.

Presentations

PDF version
Wednesday, 23 October

10:50

Oral presentation

NIDA International Program Research Update

10:50 to 12:20
Auditorium VI
Tom Clarke

Oral presentation

Managing Benzodiazepine Dependence and High-Risk Use with Opiates: A feasibility study of a Co-produced Intervention

10:50 to 12:20
Auditorium II
Catriona Matheson

Oral presentation

Treatment of benzodiazepine withdrawal through taper dosing is most successful when it lasts less than 6 months.

10:50 to 12:20
Auditorium II
Alert Drishti

Oral presentation

Understanding the research capacity of Australian alcohol and other drug services

10:50 to 12:20
Auditorium VI
Robert Stirling

Oral presentation

Report from LX24 side event - Strengthening networks and sharing innovation in practices on research and surveillance in the drugs field

10:50 to 12:20
Auditorium VI
Vickna Kasinather
Charles Parry

Oral presentation

The effectiveness of naloxone in reversing opioid overdose: The European naloxone outcome research study (NalPORS)

10:50 to 12:20
Auditorium II
Nicola Metrebian

Oral presentation

A global perspective on the emotions associated with chemsex practice to better support the community

10:50 to 12:20
Auditorium IV
Yannick Gaudette

Oral presentation

Addiction and financial burden: Longitudinal 6-time point analysis of risk factors for debt enforcement in Finland

10:50 to 12:20
Room 5B
Atte Oksanen

Oral presentation

Addressing gender, diversity, and precarity: participatory research to transform addiction services in Canada

10:50 to 12:20
Auditorium IV
Karine Bertrand

Oral presentation

Bipolar disorder and severe poisoning due to medicines or illicit substances

10:50 to 12:20
Auditorium VII
Aleksi Hamina

Oral presentation

Bringing law enforcement officers (LEO) closer to other agents of prevention: A UNODC Guiding Document

10:50 to 12:20
Room 5A
Ali Yassine

Oral presentation

Chemsex Professional Training Program in Catalonia

10:50 to 12:20
Auditorium IV
Elena Adán Ibáñez

Oral presentation

CHildren AMplified Prevention Services (CHAMPS): Amplify Children Resilience through a comprehensive prevention system

10:50 to 12:20
Room 5A
Ali Yassine

Oral presentation

Cultural safety and telecare. A systematic scoping review and sector survey

10:50 to 12:20
Auditorium III
Rodrigo Ramalho

Oral presentation

Drug Consumption Rooms in Europe. Operational characteristics, capacities, services and its associated factors.

10:50 to 12:20
Auditorium III
Joana Moura

Oral presentation

Enhanced self-efficacy in HCV management: educating a multidisciplinary drug and alcohol workforce in Europe and Canada

10:50 to 12:20
Room 5C
Emma Day

Oral presentation

Enhancing Capacity for Comprehensive Drug Use Response in Humanitarian Settings

10:50 to 12:20

Oral presentation

Exploring Australian addiction workers' views on inclusive treatment for transgender and gender diverse (TGD) clients.

10:50 to 12:20
Room 5C
Nic Robinson-Griffith

Oral presentation

Foundations of Prevention Science and Practice Curriculum: Providing Technical Assistance through Training

10:50 to 12:20
Room 5C
Maria Paula Luna Jimenez

Oral presentation

Gambling Disorder and Work Disability: A National Registry Study in Sweden

10:50 to 12:20
Room 5B
Viktor Mansson

Oral presentation

Hazardous substance use and mental health among refugees in shared accommodations – a mixed-methods study

10:50 to 12:20
Auditorium VII
Miriam Lorenz

Oral presentation

Lisdexamfetamine in the treatment of methamphetamine dependence, a randomised controlled trial

10:50 to 12:20
Auditorium II
Nadine Ezard

Oral presentation

Modelling the wider socio-economic costs of problematic opioid use in the UK

10:50 to 12:20
Auditorium VIII
George Keel

Oral presentation

Prevalence of opioid dependence in Scotland, 2015-2020: results from a Multi Parameter Estimation of Prevalence model

10:50 to 12:20
Auditorium VIII
Hayley Jones

Oral presentation

Problem Gambling Among Criminal Sanction Clients: Project Overview

10:50 to 12:20
Room 5B
Sari Castrén

Oral presentation

Scaling up Harm Reduction: Results of the 3-year Take-Home Naloxone project NALtrain in Germany.

10:50 to 12:20
Room 5C
Simon Fleißner

Oral presentation

Substance Use, Sexual Pleasure and Recovery among gbMSM: Addressing Sexual Satisfaction in Addiction Interventions

10:50 to 12:20
Auditorium IV
Maxime Blanchette

Oral presentation

Suicide-related service presentations following residential treatment for substance use disorders: a data linkage study

10:50 to 12:20
Auditorium VII
Calvert Tisdale

Oral presentation

The gendered impacts of drug stigma - a qualitative study with 10 street-involved women who use drugs in Porto

10:50 to 12:20
Auditorium IV
Cristiana Vale Pires

Oral presentation

The impact of severe mental illness on treatment retention and all-cause mortality of people in opioid agonist treatment

10:50 to 12:20
Auditorium VII
Nicola Jones

Oral presentation

The reciprocal effects of gambling expenditure and crime.

10:50 to 12:20
Room 5B
Don Weatherburn

Oral presentation

The role of physical activity in preventing relapse: the perception of participants

10:50 to 12:20
Auditorium III
Florence Piché

Oral presentation

The Staying Safe Programme: A new online education approach to reducing drug related harm for university students

10:50 to 12:20
Room 5A
Adam Winstock

Oral presentation

Twenty-one years of heroin-related mortality in Australia: Joinpoint regression analysis of trends by age and gender

10:50 to 12:20
Auditorium VIII
Amanda Roxburgh

Oral presentation

Underestimate of deaths due to specific opioids in England and Wales for a decade

10:50 to 12:20
Auditorium VIII
Shuoqi Chen

Oral presentation

User experiences of a digital intervention among individuals on opioid use disorder treatment in Kenya

10:50 to 12:20
Auditorium III
Sarah Kanana Kiburi

Oral presentation

“Good health has nothing to do with alcohol”: perceptions and impacts of a French alcohol prevention campaign

10:50 to 12:20
Room 5A
Guillemette Quatremere

13:20

Oral presentation

Engaging governments and providing technical assistance

13:20 to 14:50
Room 5C
Goodman Sibeko

Oral presentation

Why is a gender perspective needed in the drug field? Insight from the latest European drugs data.

13:20 to 14:50
Auditorium VIII
Linda Montanari

Oral presentation

Regional activity undertaken by the African Union

13:20 to 14:50
Room 5C
Abel Basutu

Oral presentation

Structure and predictive validity of alcohol use disorder recovery domains in young adulthood

13:20 to 14:50
Auditorium II
George Richardson

Oral presentation

An 11-year analysis of alcohol-related emergency department presentations by young people, from an EU hospital setting

13:20 to 14:50
Auditorium II
Marie Hyland

Oral presentation

Developing the Addiction Workforce in Africa: Progress and Issues

13:20 to 14:50
Room 5C
Kevin Mulvey

Oral presentation

Building a substance use workforce network in Africa

13:20 to 14:50
Room 5C
Rasha Abi Hana

Oral presentation

Heavy episodic drinking among French adolescents between 2005 and 2022: a gender perspective.

13:20 to 14:50
Auditorium II
Eric Janssen

Oral presentation

Bridging the Gap: Exploring School Survey Data in Drug Policy and Prevention - Insights from the ESPAD-MedSPAD Project

13:20 to 14:50
Room 5A
Elisa Benedetti

Oral presentation

Changes in cannabis potency and cannabis-related harms: A 22-year ecological study in Denmark

13:20 to 14:50
Room 1.07
Kristine Rømer Thomsen

Oral presentation

Deficits in cognitive functions across different types of Internet-use disorders: Gender-related differences

13:20 to 14:50
Room 5B
Silke M. Müller

Oral presentation

Developing and operationalising a multi-component drug outreach service for young people aged 16-25 in England

13:20 to 14:50
Room 5A
Zoe Welch

Oral presentation

Digital components in interventions aiming to reduce or prevent alcohol use among young people: A scoping review.

13:20 to 14:50
Auditorium II
Stefanie Maria Helmer

Oral presentation

Drug-induced homicide laws in the US: current trends, stakeholder opinions, and public health impacts

13:20 to 14:50
Auditorium VI
Jennifer Carroll

Oral presentation

Effect of acute stress on cue reactivity and craving in online buying-shopping disorder and social network use disorder

13:20 to 14:50
Room 5B
Elisa Wegmann

Oral presentation

Gender Compression Over Time in Measures of Cannabis Use by Age and Cohort in the United States

13:20 to 14:50
Auditorium VIII
Michael Vuolo

Oral presentation

Global coverage of interventions to prevent and manage injecting drug use related harms in prisons: a systematic review

13:20 to 14:50
Auditorium VI
Thomas Santo Jr.

Oral presentation

Judge Demographics and Their Impact on Sentencing of Drug Crimes

13:20 to 14:50
Auditorium IV
Sarah Henry Davis

Oral presentation

Levels of toxicants among people who vape, smoke, dual use, or do neither among people with and without psychosis.

13:20 to 14:50
Auditorium VII
Eve Taylor

Oral presentation

Leximetric analysis of drug laws and evaluation of outcomes: cross-country analyses approach

13:20 to 14:50
Auditorium IV
Carla Rossi

Oral presentation

MATPACT: An innovative approach to finding Scotland’s forgotten generation

13:20 to 14:50
Auditorium VI
Marion Gillies

Oral presentation

Navigating the Shift: Understanding the Dynamics of Cannabis Use in Germany Amidst Legalization Prospects

13:20 to 14:50
Auditorium IV
Sally Olderbak

Oral presentation

Pharmacology of generic ban-evading synthetic cannabinoid receptor agonists: are new compounds spicing up the market?

13:20 to 14:50
Room 1.07
Marie Deventer

Oral presentation

Policy and Practice Responses to Drug-Related Deaths: Governance issues in English and Welsh Prisons, 2015-2021

13:20 to 14:50
Auditorium VI
Karen Duke

Oral presentation

Proximal and distal cues in social network use disorder: the interplay of cue-reactivity, craving, and acute stress

13:20 to 14:50
Room 5B
Annica Kessling

Oral presentation

Psychological distress, tobacco smoking and alcohol use: a population survey in Great Britain

13:20 to 14:50
Auditorium VII
Erikas Simonavičius

Oral presentation

Risk and protective factors in adolescents: adapting Communities that Care Youth Survey for Portuguese context

13:20 to 14:50
Room 5A
Susana Henriques

Oral presentation

Risk factors for the gambling, smoking and alcohol consumption triad: an observational study in Portuguese adolescents

13:20 to 14:50
Room 5A
Pedro Ramos

Oral presentation

Smokers’ careers and mental health: overlapping perspectives on cannabis and tobacco use

13:20 to 14:50
Auditorium VII
Joana Sisternas-Tusell

Oral presentation

Smoking and nicotine use behaviours among women of reproductive age: a ten-year population study in England

13:20 to 14:50
Auditorium VIII
Sharon Cox

Oral presentation

The challenge of cannabis quantification: from theory to practice

13:20 to 14:50
Room 1.07
Cláudia Sousa-Reis

Oral presentation

The effects of legislative measures for 3-MMC in the Netherlands on drug sample composition and self-reported effects.

13:20 to 14:50
Auditorium IV
Pieter Oomen

Oral presentation

The Neurobiological and Neuropsychological Link Between Gambling Disorder and Substance Abuse

13:20 to 14:50
Room 5B
Gisela Simões

Oral presentation

The perspective of transgender and non-binary people on their substance use trajectories and resilience processes

13:20 to 14:50
Auditorium VIII
Abdelhakim Missoum

15:00

Oral presentation

Increased hepatitis C and HIV incidence among people who inject drugs in Montreal, Canada, 2011-2023

15:00 to 16:30
Auditorium IV
Sarah Larney

Oral presentation

Alcohol Mis(Use) among Migrants, Asylum-seekers and Refugees: state-of-the-art

15:00 to 16:30
Auditorium II
Maria Pires Cameira

Oral presentation

Canada synthetic opioids situation

15:00 to 16:30
Auditorium VIII
Pam Kent

Oral presentation

Emerging drug trends – what are the issues and how can we strengthen preparedness

15:00 to 16:30
Auditorium VIII
Paul Griffiths

Oral presentation

Harm reduction interventions and Indigenous peoples: The first Managed Alcohol Program in Montreal

15:00 to 16:30
Auditorium II
Rossio Motta-Ochoa

Oral presentation

Predictors of outcome in individuals with alcohol use disorder and a treatment goal of controlled drinking

15:00 to 16:30
Auditorium II
Anders Hammarberg

Oral presentation

The U.S. international perspective including the Global Coalition

15:00 to 16:30
Auditorium VIII
Charlotte Sisson

Oral presentation

Crafting the international standard: Establishing and implementing core outcome measures for alcohol brief interventions

15:00 to 16:30
Auditorium II
Gillian W. Shorter

Oral presentation

US experience with synthetic drugs

15:00 to 16:30
Auditorium VIII
Christopher M. Jones

Oral presentation

"Boxing Clever Cork saved my life": an evaluation of an Irish early addiction recovery initiative

15:00 to 16:30
Auditorium III
Rebekah Brennan

Oral presentation

A Safer Downtown for All: Including People Who Use Drugs in the Solutions to Social Disorder

15:00 to 16:30
Auditorium III
Rob Boyd

Oral presentation

Acute drug-toxicity presentations involving crack cocaine to Euro-DEN Plus sentinel hospitals in Europe from 2014-2022

15:00 to 16:30
Room 5A
Isabelle Giraudon

Oral presentation

Antipsychotics and relapse risk in persons with first-episode psychosis and co-occurring cannabis use disorder

15:00 to 16:30
Auditorium VII
Heidi Taipale

Oral presentation

Associations of alcohol consumption with long-term mortality of ART-naïve persons seeking HIV care. 

15:00 to 16:30
Auditorium IV
Daniel Fuster

Oral presentation

Building Capacity For Future Evaluation of Residential Treatment for People Experiencing Homelessness and Addiction

15:00 to 16:30
Auditorium III
Ed Addison

Oral presentation

Cannabinoid Use Experience among inpatients with psychotic symptoms – A Cross-Sectional study in a Portuguese Hospital

15:00 to 16:30
Auditorium VII
Carolina Afonso Romano

Oral presentation

Challenges and support needs among persons with a migration background who use drugs in four metropolitan cities

15:00 to 16:30
Room 5C
Wouter Vanderplasschen

Oral presentation

Considering the prevention workforce: a study on practitioner needs when recommending substance use interventions

15:00 to 16:30
Room 1.06
Natalie Blackburn

Oral presentation

Decentralized consultation for infectious diseases with at-risk populations: preliminary results

15:00 to 16:30
Auditorium IV
Paulo Caldeira

Oral presentation

Documenting major shifts in methamphetamine and heroin prices and purity in metropolitan and rural Victoria, Australia

15:00 to 16:30
Auditorium VI
Kasun Rathnayake

Oral presentation

Drug markets and financial flows: underground banking in the Netherlands

15:00 to 16:30
Auditorium VI
Nienke Liebregts

Oral presentation

Drug poisoning deaths of under 30-year-olds – Key issues in the cause of death investigation documents

15:00 to 16:30
Room 5A
Sanna Rönkä

Oral presentation

Drug use and (non-)use of addiction treatment by women in French Guyana: gender and migration effects

15:00 to 16:30
Room 5C
Estelle Filipe

Oral presentation

Effects of recreational cannabis versus black market: A randomized controlled trial in Switzerland (WEED CARE)

15:00 to 16:30
Auditorium VI
Lavinia Baltes

Oral presentation

Evaluating and comparing health quality for addiction treatment in the Lazio region, Italy

15:00 to 16:30
Room 1.06
Antonella Camposeragna

Oral presentation

How do purity and price of cocaine affect consumption in Austria?

15:00 to 16:30
Auditorium VI
Birgit Priebe

Oral presentation

How do you make it work? A pragmatic framework for the Sustained Uptake of Service Innovations (SUSI).

15:00 to 16:30
Room 1.06
Catherine Foley

Oral presentation

Instruments assessing Gaming Disorder in children and adolescents – A systematic review of psychometric properties

15:00 to 16:30
Room 5B
Samantha Schlossarek

Oral presentation

Migrants in the criminal justice system: A qualitative understanding of the role of substance use in their lives

15:00 to 16:30
Room 5C
Marjolein De Pau

Oral presentation

Mortality among first-time opioid agonist therapy patients in Austria, 2002-2021: A national retrospective cohort study

15:00 to 16:30
Room 5A
Tanja Schwarz

Oral presentation

Mothers receiving substance use treatment involved in care proceedings: A record linkage cohort study

15:00 to 16:30
Room 5A
Martha Canfield

Oral presentation

Planning and Monitoring drug and alcohol treatment in Denmark. The MapPlan project.

15:00 to 16:30
Room 1.06
Mads Uffe Pedersen

Oral presentation

Psychoactive Substance Use Among Russian Migrants Relocated to Georgia Following the 2022 Ukrainian Invasion

15:00 to 16:30
Room 5C
David Otiashvili

Oral presentation

Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis

15:00 to 16:30
Auditorium VII
Antti Mustonen

Oral presentation

Refugees & drug use in Belgium: A national study on drug-related intervention needs in the reception setting (DrugInt)

15:00 to 16:30
Room 5C
Charlotte de Kock

Oral presentation

Screening Measures on Internet Use Disorders in Children and Adolescents - A Delphi Study

15:00 to 16:30
Room 5B
Hans-Juergen Rumpf

Oral presentation

Superiority and cost-effectiveness of Individual Placement and Support for people with alcohol and drug dependence

15:00 to 16:30
Auditorium III
John Marsden

Oral presentation

The Gaming Disorder Identification Test (GADIT) - A screening tool for Gaming Disorder based on ICD-11

15:00 to 16:30
Room 5B
Gary Chan

Oral presentation

The Problematic Behaviour Scale (PBS-10): psychometric characteristics and cut-offs using Swiss national survey data

15:00 to 16:30
Room 5B
Sebastian Mader

Oral presentation

“Into a whirlwind”: Navigating psychosis and anti-psychotic treatment among youth entrenched in an urban drug scene

15:00 to 16:30
Auditorium VII
Trevor Goodyear

Oral presentation

“They kicked me out of hospital twice”: barriers and facilitators accessing care with an injecting-related infection

15:00 to 16:30
Auditorium IV
Samantha Colledge-Frisby

16:50

Oral presentation

Application of the International Standards for the Treatment of Drug Use Disorders and the Key Quality Standards for service appraisal

16:50 to 18:20
Auditorium II
Anja Busse

Oral presentation

International Consortium on Quality in Substance Use Disorders Treatment

16:50 to 18:20
Auditorium II
Rita Notarandrea

Oral presentation

Insights from the Recipient of the first ICQ Quality Seal Award

16:50 to 18:20
Auditorium II
Michael W. Johnson

Oral presentation

PIQAT: Program for International Quality Assurance in Treatment

16:50 to 18:20
Auditorium II
Mariano Montenegro

Oral presentation

(De)criminalisation of drug possession as a litmus test of national drug policy? Experience from the Czech Republic

16:50 to 18:20
Auditorium VI
Petr Zeman

Oral presentation

20-year trends in Australian methamphetamine-related deaths: An age–period–cohort–interaction analysis

16:50 to 18:20
Auditorium IV
Oisin Stronach

Oral presentation

A Collaborative Approach to New Drug Identification in an Emerging Drug Early Warning System

16:50 to 18:20
Auditorium III
Donna Papsun

Oral presentation

Achieving universal health coverage of opioid agonist treatment in Norway: a cost-utility analysis

16:50 to 18:20
Room 5B
Prayash Chaudhary

Oral presentation

Adolescents spending time with their parents: does it matter to prevent risky and addictive behaviors?

16:50 to 18:20
Room 5A
Ina Koning

Oral presentation

AN IMPLEMENTATION SCIENCE EVALUATION OF SCOTLAND’S FIRST HEROIN ASSISTED TREATMENT (HAT) FACILITY

16:50 to 18:20
Room 5B
Andrew McAuley

Oral presentation

Assessing quality of substance use treatment in legal settings: lessons from United States drug courts

16:50 to 18:20
Auditorium VI
Steven Belenko

Oral presentation

Codeine, oxycodone, and tramadol prescription prior to overdose deaths compared to toxicological findings

16:50 to 18:20
Auditorium IV
Hilde Edvardsen

Oral presentation

Comorbidity of substance use disorders and other mental health disorders: towards a common European approach

16:50 to 18:20
Auditorium VII
Marta Torrens

Oral presentation

Development of a mobile neuroscience-informed psychoeducation program for resilience and substance use prevention

16:50 to 18:20
Room 5A
Jasmin Vassileva

Oral presentation

Effects of cannabis use timing and formulation on sleep among young adults who report high-intensity alcohol use

16:50 to 18:20
Auditorium VII
Elizabeth R. Aston

Oral presentation

Emergence of semi-synthetic cannabinoids in Europe – a perspective from the European Union Early Warning System

16:50 to 18:20
Auditorium III
Rachel Christie

Oral presentation

Examining Associations Between Alcohol and Cannabis Simultaneous and Concurrent Co-Use and Mental Health Outcomes

16:50 to 18:20
Auditorium VII
Bradley Conner

Oral presentation

Exploring social-environmental factors in recovery and reintegration of substance-related disorders: a scoping review

16:50 to 18:20
Room 5A
Mariana Vieira

Oral presentation

Heavy drinking among ‘sober generation’ youth: a longitudinal study

16:50 to 18:20
Room 5C
Marit Edland-Gryt

Oral presentation

Law Enforcement Encounters and Decriminalization Gaps: Insights from People Who Use Drugs in Oregon Post-Measure 110

16:50 to 18:20
Auditorium VI
Morgan Godvin

Oral presentation

Medical use of psychedelic substances: EUDA's monitoring of key developments

16:50 to 18:20
Auditorium VIII
Alexander Söderholm

Oral presentation

Monitoring intravenous drugs use in Spain through syringe residue analysis

16:50 to 18:20
Auditorium IV
Carlos Pernas-Fraguela

Oral presentation

Motivations for cocaine use: relation with drug use patterns, risks and how this informs prevention

16:50 to 18:20
Room 5C
Eva Blomme

Oral presentation

Motivations underlying co-use of benzodiazepines and opioids in the UK: a qualitative study

16:50 to 18:20
Room 5C
Gaby Vojt

Oral presentation

Parents aren’t out of the picture: Parent factors are linked with heavy episodic drinking among high school students

16:50 to 18:20
Room 5A
Lotte Vallentin-Holbech

Oral presentation

Police drug diversion in England and Wales: Findings from a realist process evaluation

16:50 to 18:20
Auditorium VI
Alex Beerjeraz

Oral presentation

Quantifying and expanding alternatives to arrest for use and possession offences for illicit drugs

16:50 to 18:20
Auditorium VI
Caitlin Hughes

Oral presentation

Reduced health care utilization after entering opioid agonist treatment; change in mental and somatic health domains

16:50 to 18:20
Room 5B
Thomas Clausen

Oral presentation

Route-Dependent Subjective Effects of Medical Heroin in HAT: Implications for Treatment Trajectories

16:50 to 18:20
Room 5B
Silvana De Pirro

Oral presentation

Self-therapeutic use of psilocybin, MDMA and ketamine among Dutch nightlife attendees.

16:50 to 18:20
Auditorium VIII
Frederiek Schutten

Oral presentation

Synthetic cathinones in drug-related deaths – an alarming issue or triviality?

16:50 to 18:20
Auditorium III
Ilkka Ojanperä

Oral presentation

The relationship between self-reported childhood maltreatment and mental health in substance use disorders

16:50 to 18:20
Auditorium VII
Aleksander Hagen Erga

Oral presentation

The U.S. Psilocybin Landscape: Policy Evolution and Nationally Representative Insights

16:50 to 18:20
Auditorium VIII
Beau Kilmer

Oral presentation

Trends in GHB use and harms in Australia

16:50 to 18:20
Auditorium III
Rachel Sutherland

Oral presentation

What are the reasons for injecting methadone? A qualitative study among people who inject drugs in Barcelona

16:50 to 18:20
Auditorium IV
Gabriela Barbaglia

Oral presentation

‘Russian Roulette’: how do people who co-use benzodiazepines and opioids experience the absence of harm reduction?

16:50 to 18:20
Room 5C
Hannah Poulter
Thursday, 24 October

10:50

Oral presentation

Crisis in the race to hepatitis C elimination: modelling futures without disease

10:50 to 12:20
Auditorium VIII
Kari Lancaster

Oral presentation

Long-acting injectable buprenorphine for opioid use disorder: key findings from a longitudinal qualitative study

10:50 to 12:20
Auditorium IV
Joanne Neale

Oral presentation

Neurobiological Markers of Alcohol Use Disorder: Implications for Prevention and Treatment

10:50 to 12:20
Auditorium II
Jorge Martins

Oral presentation

Identifying harmful alcohol use with phosphatidylethanol 16:0/18:1 in patients with suspected severe injury

10:50 to 12:20
Auditorium II
Benedicte Joergenrud

Oral presentation

Adapting Opioid Therapy: Transition from Methadone to Slow-Release Morphine Amid COVID-19 Supply Chain Disruptions

10:50 to 12:20
Auditorium IV
Artūras Barkus

Oral presentation

Endgames: Disease eliminations and their politics

10:50 to 12:20
Auditorium VIII
Tim Rhodes

Oral presentation

VALIDATION OF PLASMA BIOMARKERS FOR PREDICTING AND PREVENTING ALCOHOL-ASSOCIATED RISK OF DEMENTIA: PRELIMINARY DATA

10:50 to 12:20
Auditorium II
Fernando Rodriguez de Fonseca

Oral presentation

A Global Perspective on Treatment Service Provision for Opioid Use Disorders

10:50 to 12:20
Auditorium III
Arash Khojasteh Zonoozi

Oral presentation

A Holistic Multi-Disciplinary Healthcare Pathway for Older Men who use Anabolic Androgenic Steroids

10:50 to 12:20
Room 1.08
Evelyn Hearne

Oral presentation

A wastewater-based approach to monitor shifting trends in illicit drugs consumption in Switzerland

10:50 to 12:20
Room 5A
Livia Andrani

Oral presentation

Cannabis policy and practice in Finland: from social media discussions to citizens initiatives

10:50 to 12:20
Room 1.08
Aleksi Hupli

Oral presentation

Clinicians’ experience of providing heroin-assisted treatment: Key rewards and challenges

10:50 to 12:20
Room 5C
Rune Ellefsen

Oral presentation

Drink and be merry? The impact of alcohol and affective social cues on emotional contagion

10:50 to 12:20
Auditorium II
Rebecca Monk

Oral presentation

Drugs and climate change: knowledge gaps in monitoring environmental impacts of drugs

10:50 to 12:20
Room 1.08
Tim Surmont

Oral presentation

European Hair Drug Analisys Network – A pioneer study to investigate the use of NPS and NSO

10:50 to 12:20
Room 5A
Elisa Fornero

Oral presentation

Fostering Community: A Mixed Method Analysis of Kosmicare's Mobile Drug Checking Service in Lisbon, Portugal

10:50 to 12:20
Room 5C
Helena Valente

Oral presentation

Health-related quality of life trajectories of patients in heroin-assisted treatment

10:50 to 12:20
Auditorium III
Francesca Melis

Oral presentation

Impact of long-acting depot buprenorphine post-release from custody– Early findings from the Release Study

10:50 to 12:20
Auditorium IV
Adrian Dunlop

Oral presentation

Key challenges for alcohol epidemiology and alcohol control policy evaluation

10:50 to 12:20
Auditorium VI
Jürgen Rehm

Oral presentation

Legally grey? Drug checking perspectives in the CEECA region

10:50 to 12:20
Auditorium VI
Eliza Kurcevič

Oral presentation

Opioid disorder treatment outcomes — the OPTIMUS international consensus on evidence-based and patient-centred care

10:50 to 12:20
Auditorium III
Lucas Wiessing

Oral presentation

Perceptions of family physicians in Istanbul on e-cigarettes as smoking cessation aids

10:50 to 12:20
Room 1.08
Melis Selamoglu

Oral presentation

Prevention of hazardous substance use among refugees – digital tools for the workforce in refugee aid

10:50 to 12:20
Room 5C
Jonathan Uricher

Oral presentation

Public health for whom? Unpacking the assumptions and silences in Canada's public health approach to substance use.

10:50 to 12:20
Auditorium VI
Sophie Henderson

Oral presentation

Synthesis of multisource data for the development of an advanced dashboard to monitor illicit drugs markets

10:50 to 12:20
Room 5A
Pierre Esseiva

Oral presentation

The Costs and Harms of Substance Use in Canada: Key Trends from 2007 to 2022

10:50 to 12:20
Auditorium VI
Pam Kent

Oral presentation

The situation of Harm Reduction in Spain: a qualititive approach incluying PWUD

10:50 to 12:20
Room 5C
Ester Aranda

Oral presentation

Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022

10:50 to 12:20
Auditorium III
Michael Farrell

Oral presentation

What can Portugal do to prevent be caught off guard again in the drug domain?

10:50 to 12:20
Room 5A
Alcina Correia

13:20

Oral presentation

Practical overview of management including naloxone dosing. Illustration with cases related to potent synthetic opioids, St Thomas’ hospital, 2023.

13:20 to 14:50
Auditorium VIII
Paul Dargan

Oral presentation

Looking Ahead: Future Priorities for Cannabis Research, Public Education, and Prevention

13:20 to 14:50
Auditorium IV
Shea Wood

Oral presentation

Overview of the Cannabis Act and Cannabis Regulations

13:20 to 14:50
Auditorium IV
Robert Gabrys

Oral presentation

Post-mortem analytical findings and characteristics of the nitazene-related deaths cases, Finland, 2023

13:20 to 14:50
Auditorium VIII
Kriikku Pirkko

Oral presentation

A Review of the Public Health and Safety Impacts of Cannabis of Legalization and Key Recommendations

13:20 to 14:50
Auditorium IV
Justine Renard

Oral presentation

Acute drug toxicity outbreak with nitazenes involved in prison setting and the community, La Réunion, France, June-July 2023

13:20 to 14:50
Auditorium VIII
Joris Guyon

Oral presentation

Acute nitazene-toxicity presentations to hospital emergency services, Dublin, Ireland, November 2023 outbreak

13:20 to 14:50
Auditorium VIII
Adrian Moughty

Oral presentation

Dynamic associations between anxiety and alcohol use from early adolescence to young adulthood.

13:20 to 14:50
Auditorium VII
Margot Peeters

Oral presentation

A mixed methods systematic review of interventions for women in the perinatal period, who are dependent on drugs

13:20 to 14:50
Room 5B
Emma Smith

Oral presentation

A randomized controlled trial of support programs for parents of treatment-refusing substance using young adults

13:20 to 14:50
Auditorium VII
Ola Siljeholm

Oral presentation

Associations between opioid agonist therapy exposure and chronic pain characteristics among people who inject drugs

13:20 to 14:50
Auditorium IV
Sasha Udhesister

Oral presentation

Cannabis use disorder and the brain: The role of cross-cultural differences in cannabis attitudes

13:20 to 14:50
Auditorium III
Janna Cousijn

Oral presentation

Community-wide effects of building a resilient community healthcare workforce

13:20 to 14:50
Room 5C
Carol Jones

Oral presentation

Conceptualising the right to health in the context of the world drug problem

13:20 to 14:50
Auditorium VI
Alison Ritter

Oral presentation

Differential effects of left and right insula inhibition on craving and cognitive control in regular smokers

13:20 to 14:50
Auditorium III
Mieke Schulte

Oral presentation

Drug-related deaths among housed and homeless individuals in the UK and the USA

13:20 to 14:50
Auditorium IV
Emmert Roberts

Oral presentation

Drug-related mortality associated with gabapentinoid/Z-drug co-prescribing among opioid-agonist treatment recipients

13:20 to 14:50
Auditorium IV
Megan Glancy

Oral presentation

EXPERIENCES OF DRUG CONSUMPTION ROOM PROFESSIONALS

13:20 to 14:50
Room 5C
Patricia Domingos Belo

Oral presentation

Female-specific trends and treatment needs for substance use disorder among homeless and at-risk females

13:20 to 14:50
Room 1.08
Anne Marie Carew

Oral presentation

Gender and drugs: Experiences of stigma/toxicophobia and narcofeminist narratives

13:20 to 14:50
Room 1.08
Marie Jauffret-Roustide

Oral presentation

High body mass index is prevalent in people with opioid use disorder in Northern England and increases risk of death

13:20 to 14:50
Auditorium IV
Caroline Copeland

Oral presentation

Innovation in caring for individuals experiencing polydrug use disorder: opportunities to understand multi-morbidities

13:20 to 14:50
Room 5C
Alexander Baldacchino

Oral presentation

International drug policy constellations: exploring the role of power and morality in international drug policy debates

13:20 to 14:50
Auditorium VI
Alex Stevens

Oral presentation

Peripheral endocannabinoids and related lipids in individuals with chronic non-medical prescription opioid use

13:20 to 14:50
Auditorium III
Sara Kroll

Oral presentation

Policy Responses to Drug-Related Deaths: The power of numbers?

13:20 to 14:50
Auditorium IV
Lena Eriksson

Oral presentation

Policy responses to drug-related deaths: Using a Social Determinants of Health framework analysis to inform policy

13:20 to 14:50
Auditorium VI
Aileen O'Gorman

Oral presentation

Pregnancy-related hospitalisation among women who inject drugs in Melbourne, Australia

13:20 to 14:50
Room 5B
Ashleigh Stewart

Oral presentation

Squandered sexenio: applying drug policy constellations to the failure of marijuana legalization in Mexico (2018-2024)

13:20 to 14:50
Auditorium VI
Jonas von Hoffmann

Oral presentation

Substance use variation among LGBTQ+ youth: stress, resilience and ecosystemic intervention

13:20 to 14:50
Auditorium VII
Julie-Christine Cotton

Oral presentation

The care pathways of women who use drugs in the perinatal period. Findings of a qualitative, longitudinal study

13:20 to 14:50
Room 5B
Polly Radcliffe

Oral presentation

The genetic etiology of cannabis use: from twin models to genome-wide association studies and beyond

13:20 to 14:50
Auditorium III
Karin J. H. Verweij

Oral presentation

The perinatal period as a window of opportunity for change and recovery? A study of mothers and relatives' accounts

13:20 to 14:50
Room 5B
Sarah Vandewalle

Oral presentation

Understanding substance use and affective symptoms in late adolescents in an urban context: A network approach

13:20 to 14:50
Auditorium VII
Helle Larsen

Oral presentation

Unveiling the Nexus of Addiction, Violence, and Risk: Generational Patterns in Female Populations

13:20 to 14:50
Room 1.08
Sabrina Molinaro

Oral presentation

Vulnerabilities and agencies of women who use and sell drugs in Bordeaux and Montréal

13:20 to 14:50
Room 1.08
Sarah Perrin

Oral presentation

What do clinicians think about psychedelic assisted therapy? An Australian perspective.

13:20 to 14:50
Room 5C
Zachary Bryant

15:00

Oral presentation

Experiences of building a Prompt Response Network for emerging drugs of concern in Australia

15:00 to 16:30
Room 1.05
Brendan Clifford

Oral presentation

Psychosocial Care

15:00 to 16:30
Room 5C
Paul O'Brien

Oral presentation

ACCS complexity of care provision

15:00 to 16:30
Room 5C
Jacob Krzanowski

Oral presentation

Emerging Drug trends in Japan: rethinking prevention strategies

15:00 to 16:30
Room 1.05
Hironobu Fujiwara

Oral presentation

Socioeconomic differences in the real-world effectiveness of pharmacotherapy of alcohol-related health problems

15:00 to 16:30
Auditorium II
Devy Elling

Oral presentation

The promised endings and missed targets of global disease elimination

15:00 to 16:30
Auditorium VIII
Sarah Larney

Oral presentation

Are the key impacts being measured? Hepatitis C elimination in Australia

15:00 to 16:30
Auditorium VIII
Gregory Dore

Oral presentation

Estimating the global burden of alcohol's harm to others

15:00 to 16:30
Auditorium II
Anne-Marie Laslett

Oral presentation

Exploring Novel Psychoactive Substances Among Kazakhstan's Youth: A Focus on Emerging Trends and Risks

15:00 to 16:30
Room 1.05
Mariya Prilutskaya

Oral presentation

The Addiction Clinical Care Suite (ACCS): service outline and 2 year outcome data

15:00 to 16:30
Room 5C
John Archer

Oral presentation

Background and establishment of the Addiction Clinical Care Suite (ACCS): a comprehensive, multi-disciplinary inpatient addiction service in London

15:00 to 16:30
Room 5C
Shantelle Quashie

Oral presentation

Economic wealth, patterns of drinking, and alcohol-attributable disease burden

15:00 to 16:30
Auditorium II
Pol Rovira

Oral presentation

The case of Kratom: from traditional medical to recreational use

15:00 to 16:30
Room 1.05
Vicknasingam Balasingam

Oral presentation

25 years of monitoring the Dutch cannabis market using chemical analys: trends, developments and technical discussion

15:00 to 16:30
Room 1.08
Pieter Oomen

Oral presentation

A comparative analysis of state-controlled models for legal cannabis sales in Uruguay and Quebec (Canada)

15:00 to 16:30
Auditorium VI
Marta Rychert

Oral presentation

A national program to scale-up decentralized HCV point-of-care testing and treatment in Australia

15:00 to 16:30
Auditorium IV
Jason Grebely

Oral presentation

A provisional evaluation of Australia’s medical cannabis framework

15:00 to 16:30
Auditorium VI
Myfanwy Graham

Oral presentation

Adverse childhood experiences and drug use in early adulthood: an analysis of the Growing Up in Ireland 1998 cohort

15:00 to 16:30
Room 5A
Deirdre Mongan

Oral presentation

Biography, age and temporality: understanding shifts in alcohol consumption over time among young abstainers

15:00 to 16:30
Room 5A
Amy Pennay

Oral presentation

Brorphine analogues as new psychoactive substances: in vitro and in vivo pharmacological characterization

15:00 to 16:30
Auditorium III
Marthe Vandeputte

Oral presentation

Consequences of cannabis legalization on use and health outcomes on the basis of international experiences

15:00 to 16:30
Auditorium VI
Uwe Verthein

Oral presentation

Dropout from addiction treatment: predictors, patient profiles, outcomes, and recommendations to improve care.

15:00 to 16:30
Auditorium VII
Marie-Josee Fleury

Oral presentation

Drug monitoring by samples seized at 2018, 2022 and 2023 BOOM festival editions

15:00 to 16:30
Room 1.08
Carla Filipa Ferreira

Oral presentation

Factors associated with cocaine use in late adolescence and young adulthood in the Growing Up in Ireland cohort study

15:00 to 16:30
Room 5A
Margaret Brennan

Oral presentation

HCV Community-led monitoring: from consultation to effective policy contributions

15:00 to 16:30
Auditorium IV
Lynn Jefferys
Joana Canedo

Oral presentation

In vitro cannabinoid activity-based screening of seized plant materials: a future-proof harm reduction strategy?

15:00 to 16:30
Auditorium III
Axelle Timmermamn

Oral presentation

LECUCA: Analysis of Brazil's largest open drug scene using time-series cross-sectional survey data

15:00 to 16:30
Room 1.08
Clarice Madruga

Oral presentation

Modelling the impact of scaling up of HCV case finding and treatment for people who inject drugs in England

15:00 to 16:30
Auditorium IV
Zoe Ward

Oral presentation

Neurotoxicity of synthetic cathinones: Can metabolism play a role?

15:00 to 16:30
Auditorium III
Alexandra Antunes

Oral presentation

Online Addictions Expert Group of the Pompidou Group: Results and Recommendations

15:00 to 16:30
Room 5B
Jann Schumacher

Oral presentation

Pharmacology of 30 semisynthetic cannabinoids – and why details matter when assessing the harm potential of seized drugs

15:00 to 16:30
Auditorium III
Christophe Stove

Oral presentation

Pilot HCV Birth Cohort Screening in UK Primary Care using a postal oral fluid home testing kit: the HEPCAPP StudyPP STUDY

15:00 to 16:30
Auditorium IV
Matt Hickman

Oral presentation

Prevention when exclusion is lifted: Intervention models from the New Swiss Gambling Act

15:00 to 16:30
Room 5B
Linda Elezi

Oral presentation

Risks and harms associated with online gaming and gambling

15:00 to 16:30
Room 5B
Eduarda Ferreira

Oral presentation

Same Intentions, Different Outcomes: Divergent Paths and Implementation Gaps in Cannabis Legalization in North America

15:00 to 16:30
Auditorium VI
Ivana Obradovic

Oral presentation

Service user and Carer perspective on Treatment for Co-Occurring Mental Health and Substance Use Problems (RECO Study)

15:00 to 16:30
Auditorium VII
Elizabeth Hughes

Oral presentation

The end of responsible gambling

15:00 to 16:30
Room 5B
Charles Livingstone

Oral presentation

The use of patient-reported outcomes in residential alcohol & drug services in Belgium: findings from the OMER-BE study

15:00 to 16:30
Auditorium VII
Amine Zerrouk

Oral presentation

Trends in illicit and licit substance use across Spain – A comprehensive three-year wastewater-based epidemiology study.

15:00 to 16:30
Room 1.08
José Benito Quintana

Oral presentation

Who is driving under the influence of cannabis in Germany? Findings of a large-scale online survey

15:00 to 16:30
Room 5A
Anna Schranz

16:50

Oral presentation

Age-related loss of autonomy, residential instability and alcohol use: suggestions to improve intervention and services

16:50 to 18:20
Auditorium VI
Vincent Wagner

Oral presentation

Epidemiology of injecting drug use and injection related harms among people who are incarcerated

16:50 to 18:20
Auditorium IV
Louisa Degenhardt

Oral presentation

Exploring drinking motives and alcohol consumption in a UK LGBTQ+ population

16:50 to 18:20
Auditorium II
Adam Qureshi

Oral presentation

Illustrating the Recovery Journey: Exploring Women's Alcohol Treatment Experiences Through Participant Drawings

16:50 to 18:20
Auditorium II
Juliette Allen

Oral presentation

Patient characteristics and treatment outcome predictors in older adults in routine care alcohol use disorder treatment

16:50 to 18:20
Auditorium VI
Silke Behrendt

Oral presentation

Investigating sex and gender differences in alcohol cue-reactivity: implications for treatment strategies?

16:50 to 18:20
Auditorium II
Anne Marije Kaag

Oral presentation

Working elements in interventions to reduce problematic alcohol use according to older adults: a realist evaluation

16:50 to 18:20
Auditorium VI
Fieke van den Bulck

Oral presentation

A systematic review examining how gender and sex are measured and reported in research on alcohol treatment

16:50 to 18:20
Auditorium II
Rodney Knight

Oral presentation

Acute drug-toxicity presentations involving polydrug use to Euro-DEN Plus sentinel hospitals in Europe from 2014 to 2022

16:50 to 18:20
Room 5B
Peter Heudtlass

Oral presentation

Cannabis liberalization is only associated with increased blunt use if states lack strong tobacco control

16:50 to 18:20
Room 5A
Brian Kelly

Oral presentation

Cocaine use on the rise – are politicians and city level services prepared for the emerging trend of crack cocaine?

16:50 to 18:20
Auditorium III
Else Kristin Utne Berg

Oral presentation

Context specific factors that impact on the optimal scale up of hepatitis C testing and treatment in the UK

16:50 to 18:20
Auditorium IV
Peter McCulloch

Oral presentation

Data collection on acute drug toxicity using the Euro-DEN plus model in countries bordering the European Union

16:50 to 18:20
Room 5B
Thomas Néfau

Oral presentation

Do minimum unit pricing policies reduce alcohol harms? A review of new evidence.

16:50 to 18:20
Room 5A
Cassandra Wright

Oral presentation

Dual diagnosis and their care pathways for help-seeking: a multi-center study from India

16:50 to 18:20
Auditorium VII
Abhishek Ghosh

Oral presentation

Impact of mental health on retention in OAT

16:50 to 18:20
Auditorium VII
Lucy Thi Tran

Oral presentation

Inpatient admissions in people with opioid dependence: a portuguese population-based observational retrospective study

16:50 to 18:20
Room 5B
José Miguel Paupério

Oral presentation

Intervention development of a nature-based programme for co-occurring mental health and substance use problems.

16:50 to 18:20
Auditorium VII
Wendy Masterton

Oral presentation

Islands in the stream: The accessibility of mental health care for persons with substance use problems in Belgium

16:50 to 18:20
Auditorium VII
Clara De Ruysscher

Oral presentation

It is time to take nitrous oxide seriously

16:50 to 18:20
Room 5C
Julaine Allan

Oral presentation

Misuse of psychoactive medicines and its harmful consequences in Portugal

16:50 to 18:20
Auditorium VIII
Ana Araújo

Oral presentation

Nangs in Australia: Investigating nitrous oxide use among people who regularly use MDMA and/or other illicit stimulants

16:50 to 18:20
Room 5C
Jodie Grigg

Oral presentation

New challenges for outpatient care: trends from twenty years of monitoring treatment demand in the city of Hamburg

16:50 to 18:20
Room 5C
Marcus Martens

Oral presentation

Non-Fatal Overdose: A Decade-Long Analysis of Inner-City Hospitals and Nationwide Trends Across Ireland (2011-2021)

16:50 to 18:20
Room 5B
Jo-Hanna Ivers

Oral presentation

Population aging and apparent decline in initiation of injecting drug use in Australia

16:50 to 18:20
Room 5C
Olivia Price

Oral presentation

Pushing the limits of tobacco control; How far can the state go in order to save us from our 'sins'?

16:50 to 18:20
Room 5A
Karl Erik Lund

Oral presentation

Responding to the identification of nitazenes within the illicit diazepam market

16:50 to 18:20
Auditorium III
Josie Smith

Oral presentation

Socioeconomic risk factors for long-term prescription opioid use: A national registry-linkage study

16:50 to 18:20
Auditorium VIII
Ingvild Odsbu

Oral presentation

The development of a toolkit to support the elimination of viral hepatitis B and C in prisons

16:50 to 18:20
Auditorium IV
Erika Duffell

Oral presentation

The impact of alcohol taxation on alcohol-attributable health inequalities in the US: a microsimulation study

16:50 to 18:20
Room 5A
Carolin Kilian

Oral presentation

Towards elimination of hepatitis C in Oslo: cross-sectional prevalence studies in 2018, 2021, 2022 and 2023

16:50 to 18:20
Auditorium IV
Eirik Opheim

Oral presentation

Understanding Drug Use in a Dutch Prison: A Call for Improved Research and Care and Lessons learned

16:50 to 18:20
Auditorium III
Daan van der Gouwe

Oral presentation

Using intensive longitudinal data to investigate predictors of cannabis and opioid use among patients with chronic pain

16:50 to 18:20
Auditorium VIII
Johannes Thrul

Oral presentation

Words vs. strands: Does the concordance of self-reported and hair-analyzed substance use of young adults change over time?

16:50 to 18:20
Auditorium III
Clarissa Janousch
MENU

Lisbon Addictions 2024